Whitehawk Therapeutics (WHWK) AI Stock Analysis

• Market Cap: $89.98M
• Dividend Yield: N/A
• Average Volume (3M): 131.69K
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.33
• Revenue Growth: 16.51%
• EPS Growth: N/A
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 1.83
• Shares Outstanding: 47,109,295
• 10 Day Avg. Volume: 101,782
• 30 Day Avg. Volume: 131,686
• PEG Ratio: 0.03
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.76
• Enterprise Value/Market Cap: -1.49
• Enterprise Value/Revenue: -1.30
• Enterprise Value/Gross Profit: 10.46
• Enterprise Value/Ebitda: 0.52
• 1Y Price Target: $2.00
• Price Target Upside: 4.71% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 57 Neutral
• Price Target: $2.00 ▲(4.71%Upside)

Whitehawk Therapeutics scores a 57, primarily influenced by its financial performance challenges, including consistent revenue growth but significant profitability issues. The technical analysis provides a moderately positive outlook with mixed indicators, while valuation suggests potential upside if operational efficiencies improve. The lack of earnings call and corporate events data limits additional insights.

Positive Factors

Financial Transactions

The company has now completed divestiture of Aadi Subsidiary to Kaken for $102MM on top of closing a $100MM PIPE.

Preclinical Progress

Whitehawk continues to make solid preclinical progress on its portfolio of next-gen ADCs as it aims for INDs for all 3 by mid-2026, and these could be differentiated.

Negative Factors

Expenses

Research and development expenses and selling, general, and administrative expenses greatly exceeded earlier estimates.

Financial Performance

Whitehawk reported a net loss of $0.67 per share for 4Q24, significantly higher than previously estimated.

Whitehawk Therapeutics Business Overview & Revenue Model

Company Description

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

How the Company Makes Money

Whitehawk Therapeutics makes money primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes partnerships with other pharmaceutical companies for joint development and commercialization efforts, licensing agreements that provide upfront payments and royalties, and potential milestone payments contingent upon successful progression of its drug candidates. Additionally, Whitehawk may derive income from grants and research funding aimed at supporting its innovative treatment programs. The company's earnings rely heavily on the successful advancement of its drug pipeline through clinical trials and eventual regulatory approval and market release.

Whitehawk Therapeutics Financial Statement Overview

Summary

Whitehawk Therapeutics demonstrates revenue growth and a stable financial structure, yet struggles with profitability and cash flow challenges. The balance sheet shows a strong equity position, but ongoing net losses and negative cash flow could pressurize future operations. The company needs to address operational inefficiencies to improve its financial health.

Income Statement

The company's income statement reveals consistent revenue growth over the years, but profitability remains a significant issue. Gross and net profit margins are negative, indicating high operational costs relative to revenue. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and challenges in reaching profitability. Despite revenue growth, the persistent net losses and high operating expenses present financial risks.

Balance Sheet

The balance sheet reflects a relatively strong equity position with a positive equity ratio. However, the company carries substantial liabilities, which, coupled with negative equity in earlier years, pose long-term risks. The debt-to-equity ratio is low, suggesting manageable debt levels. Nonetheless, the negative return on equity due to recurring net losses remains a concern.

Cash Flow

Cash flow analysis shows significant operating cash outflows, consistent with the company's lack of profitability. However, the company has maintained negative free cash flow, which could strain liquidity in the absence of financing. The operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. Despite these issues, the company has managed to maintain cash reserves through financing activities, mitigating immediate liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.77M	25.98M	24.35M	15.22M	1.12M	14.58M
Gross Profit	-12.79M	-28.07M	-27.38M	-18.78M	-18.55M	-428.00K
EBITDA	-59.66M	-64.63M	-71.76M	-58.80M	-36.96M	-2.54M
Net Income	27.61M	-63.69M	-65.77M	-60.51M	-110.09M	-3.48M
Balance Sheet
Total Assets	234.00M	70.32M	132.42M	184.24M	157.91M	18.82M
Cash, Cash Equivalents and Short-Term Investments	231.06M	47.24M	108.84M	172.56M	148.99M	4.46M
Total Debt	0.00	833.00K	1.27M	1.66M	605.00K	10.26M
Total Liabilities	12.27M	17.84M	27.23M	25.86M	21.50M	31.26M
Stockholders Equity	221.73M	52.48M	105.19M	158.38M	136.41M	-12.43M
Cash Flow
Free Cash Flow	-53.23M	-61.20M	-63.63M	-50.08M	-22.47M	-12.70M
Operating Cash Flow	-51.76M	-59.55M	-59.66M	-49.64M	-22.42M	-12.70M
Investing Cash Flow	130.15M	25.20M	83.21M	-132.89M	25.15M	0.00
Financing Cash Flow	95.34M	130.00K	326.00K	72.62M	141.80M	1.19M

Whitehawk Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Negative. The current price of 1.91 is below the 20-day moving average (MA) of 1.96, above the 50-day MA of 1.83, and below the 200-day MA of 2.18, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 50.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WHWK.

Whitehawk Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	59 Neutral	HK$15.54B	5.54	-7.44%	4.07%	11.55%	-28.15%
WHWK	57 Neutral	$89.98M	12.73	17.69%	―	16.51%	―
VERU	49 Neutral	$88.02M	―	-88.03%	―	-21.28%	36.26%
MGNX	49 Neutral	$101.58M	―	-60.25%	―	255.31%	-141.39%
SRZN	43 Neutral	$74.58M	―	-456.32%	―	―	0.13%
TNYA	36 Underperform	$111.13M	―	-76.21%	―	―	23.55%
BDTX	33 Underperform	$163.20M	46.52	4.14%	―	―	33.97%

Whitehawk Therapeutics Corporate Events

Whitehawk Therapeutics Elects Directors at Annual Meeting

Whitehawk Therapeutics, Inc. held its annual meeting of stockholders on June 11, 2025, where 61% of the voting power was represented. During the meeting, three Class II directors were elected, executive compensation was approved on an advisory basis, and BDO USA, P.C. was ratified as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (WHWK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Whitehawk Therapeutics stock, see the WHWK Stock Forecast page.